Asunto(s)
Albendazol/efectos adversos , Antihelmínticos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Anticonceptivos Orales Combinados/efectos adversos , Adolescente , Albendazol/uso terapéutico , Antihelmínticos/uso terapéutico , Cuidados Críticos , Sinergismo Farmacológico , Urgencias Médicas , Femenino , Humanos , Recurrencia , Toxocariasis/tratamiento farmacológicoRESUMEN
The objective of this study was to evaluate the safety and efficacy of bermekimab, an IL-1α inhibitor, in the treatment of hidradenitis suppurativa (HS). This study was a phase II, multicenter, open-label study of two dose cohorts of bermekimab in patients with moderate-to-severe HS who are naïve to or have failed prior anti-TNF therapy. Patients with HS (n = 42) were divided into groups A and B based on whether or not they had previously failed an anti-TNF therapy. In group A (n = 24), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in patients who had previously failed anti-TNF therapy; in group B (n = 18), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in patients who were anti-TNF naïve. Bermekimab, previously found to be effective in treating HS, was evaluated using a subcutaneous formulation in patients with HS naïve to or having failed anti-TNF therapy. There were no bermekimab-related adverse events with the exception of injection site reactions. Bermekimab was effective despite treatment history, with 61% and 63% of patients naïve to and having failed anti-TNF therapy, respectively, achieving HS clinical response after 12 weeks of treatment. A significant reduction in abscesses and inflammatory nodules of 60% (P < 0.004) and 46% (P < 0.001) was seen in anti-TNF naïve and anti-TNF failure groups, respectively. Clinically and statistically significant reduction was seen in patients experiencing pain, with the Visual Analogue Scale pain score reducing by 64% (P < 0.001) and 54% (P < 0.001) in the anti-TNF naïve and anti-TNF failure groups, respectively. IL-1α is emerging as an important clinical target for skin disease, and bermekimab may represent a new therapeutic option for treating moderate-to-severe HS.
Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Hidradenitis Supurativa/tratamiento farmacológico , Reacción en el Punto de Inyección/epidemiología , Interleucina-1alfa/antagonistas & inhibidores , Dolor/tratamiento farmacológico , Adulto , Anticuerpos Monoclonales Humanizados/efectos adversos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Hidradenitis Supurativa/complicaciones , Hidradenitis Supurativa/diagnóstico , Hidradenitis Supurativa/inmunología , Humanos , Reacción en el Punto de Inyección/etiología , Inyecciones Subcutáneas , Interleucina-1alfa/inmunología , Masculino , Persona de Mediana Edad , Dolor/diagnóstico , Dolor/inmunología , Dimensión del Dolor , Calidad de Vida , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
UNLABELLED: We describe the case of a 56-year-old man with a previously decentered laser in situ keratomileusis ablation in his right eye that induced associated vision-threatening problems. After intrastromal corneal ring segment implantation, both topography and visual acuity significantly improved. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.